BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma by Katja Gutmair, Diego Villa, Nicholas Cunningham, Elisabeth Silkenstedt, Lisa Rimsza, Colleen Ramsower, David W. Scott, Alina S. Gerrie, Hanneke C. Kluin-Nelemans, Martin Dreyling, Eva Hoster

Get full text

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance by Christian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, Martin Sökler, Roswitha Forstpointner, Christian Buske, Andreas Viardot, Ulrich Keller, Ullrich Graeven, Reinhard Marks, Mathias Hänel, Rüdiger Liersch, Jan Dürig, Christiane Pott, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann

Get full text

Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups by Ricarda Knabe, Philippe Muller, Christoph Schliemann, Maher Hanoun, Julia Marie Unglaub, Barbora Weinbergerová, Jiří Mayer, Carolin Krekeler, Stefan W. Krause, Martin Kaufmann, Sabrina Kraus, Björn Steffen, Franziska Modemann, Marion Subklewe, Veit Bücklein, Wolfgang G. Kunz, Martina Rudelius, Michael von Bergwelt-Baildon, Katja Gutmair, Eva Hoster, Tobias Herold, Christoph Röllig, Karsten Spiekermann

Get full text

Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study by Clémentine Sarkozy, Loïc Chartier, Vincent Ribrag, Remy Gressin, Christian H. Geisler, Hanneke C. Kluin-Nelemans, Catherine Thieblemont, Franck Morschhauser, François Lemonnier, Violaine Safar, Benoît Tessoulin, Lucie Oberic, Ghandi Damaj, Hervé Ghesquières, Krimo Bouabdallah, René Olivier Casasnovas, Roch Houot, Wolfram Klapper, Barbara Burroni, Christiane Pott, Marie-Hélène Delfau-Larue, Elizabeth Macintyre, Mary Callanan, Mats Jerkeman, Michael Unterhalt, Eva Hoster, Martin Dreyling, Steven Le Gouill, Olivier Hermine, Morgane Cheminant

Get full text